PRTN3 and rheumatoid arthritis: Recently, a proteomic signature implicating specific immune pathways was able to accurately differentiate progressors to RA from individuals at-risk due to family history or elevated ACPA but did not progress to RA using longitudinal measures of prospectively collected data (107).